Online inquiry

IVTScrip™ mRNA-Anti-IFNAR1, MDX-1333(Cap 1, N1-Methylpseudo-UTP, 30 nt-poly(A))   (CAT#: GTTS-WQ11158MR)

This product GTTS-WQ11158MR is a type of mRNA having 30 nt poly(A) tail and modified with Cap 1 & N1-Methylpseudo-UTP. It ecodes the monoclonal antibody that targets IFNAR1 gene. The antibody can be applied in Diffuse scleroderma research.
Specifications
Product type mRNA
Modified bases N1-Methylpseudo-UTP
5' Cap Cap 1
Species Homo sapiens
RefSeq NM_000629.3
Applications Gene therapy research
Format Powder
Quantity 100 µg
Purification oligo-dT affinity purification
Target Gene
Gene ID 3454
UniProt ID P17181
Download
Download resources about mRNA therapeutics development to boost your research.
CUSTOMER REVIEWS and Q&As

There are currently no Customer reviews or questions for IVTScrip™ mRNA-Anti-IFNAR1, MDX-1333(Cap 1, N1-Methylpseudo-UTP, 30 nt-poly(A)) (GTTS-WQ11158MR). Click the button above to contact us or submit your feedback about this product.
See other products
CAT Product Name Product Type CDs
GTTS-WQ6309MR IVTScrip™ mRNA-Anti-TNFRSF10B, CS-1008(Cap 0, N1-Methylpseudo-UTP, 30 nt-poly(A)) mRNA CS-1008
GTTS-WQ9730MR IVTScrip™ mRNA-Anti-CD3E&GPRC5D, JNJ-64407564(Cap 1, 5-Methyl-CTP, 30 nt-poly(A)) mRNA JNJ-64407564
GTTS-WQ6657MR IVTScrip™ mRNA-Anti-ITGAV, DI-17E6(Cap 0, 5-Methyl-CTP, 30 nt-poly(A)) mRNA DI-17E6
GTTS-WQ9172MR IVTScrip™ mRNA-Anti-CD37, IMGN-529(Cap 1, 5-Methyl-CTP, 120 nt-poly(A)) mRNA IMGN-529
GTTS-WQ11896MR IVTScrip™ mRNA-Anti-CCR2, MLN-1202(Cap 1, N1-Methylpseudo-UTP, 120 nt-poly(A)) mRNA MLN-1202
GTTS-WQ926MR IVTScrip™ mRNA-Anti-EGFR, ABBV-321(Cap 1, 5-Methyl-CTP & Pseudo-UTP, 30 nt-poly(A)) mRNA ABBV-321
GTTS-WQ5882MR IVTScrip™ mRNA-Anti-IFNAR1&IFNAR2, CIFN(Cap 1, 5-Methoxy-UTP, 30 nt-poly(A)) mRNA CIFN
GTTS-WQ13646MR IVTScrip™ mRNA-Anti-CD19, RB4v1.2(Cap 1, 5-Methyl-CTP & Pseudo-UTP, 30 nt-poly(A)) mRNA RB4v1.2
All products and services are For Research Use Only and CANNOT be used in the treatment or diagnosis of disease.
webinar

EABR Nanoparticles as a Platform Technology for Hybrid mRNA Vaccine Development

November 20th, 2024, 2 PM–3 PM EST

REGISTER NOW